Abstract
Introduction/Background*In the NOVA trial of niraparib maintenance treatment (MT) in platinum-sensitive recurrent ovarian cancer (PSROC), dose reduction due to treatment-emergent adverse events (TEAEs) occurred in 66.5% of patients initiating niraparib...
Full Text 
Sign-in/Register to access full text options
Sign-in/Register to access full text options 
Published version (
Free)
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callMore From: International journal of gynecological cancer : official journal of the International Gynecological Cancer Society
Paper Title
Journal
Date
